EEDQ is a carboxylate activator and irreversible antagonist of 5HT2c receptors. EEDQ reduces [3H]beta-CIT binding to the dopamine transporter (DAT) in rat caudate-putamen (CPu) homogenates (IC50 = 78.3 µM). EEDQ inhibits contralateral rotation behavior[1][2][3][4][5].